• EPH114 Willingness to Use Prep Among Prep Naïve Men Who Have Sex with Men: A Meta-Analysis and Systematic Review

    Jun 1, 2023, 00:00

  • EE473 Cost-Effectiveness of Long-Acting Cabotegravir Plus Long-Acting Rilpivirine for the Treatment of HIV-1 in Taiwan

    Jun 1, 2023, 00:00

  • HTA40 Living Network Meta-Analysis for up-to-Date Comparative Effectiveness: A Case Study in Metastatic Castration Resistant Prostate Cancer (MCRPC)

    Jun 1, 2023, 00:00

  • EE343 The Effect of BMI and the Obesity Paradox on Post-PCI Healthcare Costs and Length of Stay

    Jun 1, 2023, 00:00

  • EE436 Cystic Fibrosis Treatment Costs in a Brazilian Health Insurance Company

    Jun 1, 2023, 00:00

  • EE541 Health Equity Improvements Driven By Faricimab for the Treatment of Diabetic Macular Edema in an Aggregate Distributional Cost-Effectiveness Analysis from an English NHS Perspective

    Jun 1, 2023, 00:00

  • CO44 Scoping Review and Meta-Analysis on the Effectiveness and Safety of Powered Stapler and Manual Stapler

    Jun 1, 2023, 00:00

  • RWD117 Economic Impact of Depression Among Medicare Beneficiaries (AGE ≥65 YEARS) with Alzheimer’s Disease and Related Dementia (ADRD) in the United States (US)

    Jun 1, 2023, 00:00

  • HTA60 Potential Decision Drivers for Positive Recommendations of New Cancer Therapies in the Brazilian Private Healthcare System: Analysis of Recent HTA Submissions

    Jun 1, 2023, 00:00

  • OP11 The Influence of Extracurricular Activities on Radiology Resident Selection Decisions

    Jun 1, 2023, 00:00

  • CO211 Real-World Treatment Patterns of Early-Stage Hepatocellular Carcinoma (HCC) after Complete Resection or Ablative Therapy: Retrospective, Medical Chart Review in the United States

    Jun 1, 2023, 00:00

  • P16 A Comparison of the Cox-Proportional Hazard Model and the Fine-Gray Model to Predict Survival in Patients with Non-Small Cell Lung Cancer (NSCLC)

    Jun 1, 2023, 00:00

  • SA10 Benchmarking of Budget Impact Results: An Updated Systematic Review of US Budget Impact Analyses

    Jun 1, 2023, 00:00

  • CO95 Blood Pressure Control and Discontinuation of Antihypertensive Therapy Among Patients with Hypertension Who Initiated Sodium-Glucose Cotransporter-2 Inhibitors

    Jun 1, 2023, 00:00

  • EE330 A Cost Analysis for Major Cardiovascular Events in Influenza Vaccinated and Unvaccinated Patients after Myocardial Infarction in Colombia

    Jun 1, 2023, 00:00

  • EE544 Budget Impact Analysis of Faricimab for Treating Patients with Diabetes Macular Edema or Neovascular Age-Related Macular Degeneration in Guatemala

    Jun 1, 2023, 00:00

  • EPH249 Development of Substance Use Disorder in Chronic Kidney Disease Patients Experiencing Uremic Pruritus

    Jun 1, 2023, 00:00

  • EE176 A Cost Analysis on Complications of Fabry Disease Patients Treated with Agalsidase Alfa and Agalsidase Beta in Colombia

    Jun 1, 2023, 00:00

  • EPH94 Gender, Ethnic, and Racial Disparities Among Cell and Gene Therapy Clinical Trials

    Jun 1, 2023, 00:00

  • EE467 Prescription Patterns and Estimation of Cost of Illness of Type-II Diabetic Patients in a Tertiary Care Hospital Nepal

    Jun 1, 2023, 00:00

  • HPR121 Impact of Mandatory Prescription Drug Monitoring Program in Polysubstance-Related Admission Rate in the Substance Abuse Treatment Facilities in the United States

    Jun 1, 2023, 00:00

  • EPH9 Characterization of Demographics and Concomittant Symptoms in Patients with Post COVID-19 Conditions or Long COVID

    Jun 1, 2023, 00:00

  • PCR163 Work Productivity Impairment Among Individuals with Progressive Multiple Sclerosis

    Jun 1, 2023, 00:00

  • RWD152 Real-World Evidence on the Use of Ecmo in Hospitalized COVID-19 Patients: Results from a Linked Closed and Open Claims Database in the US

    Jun 1, 2023, 00:00

  • EE362 Systematic Review of Individual-Level Simulation in Cost-Effectiveness Analysis of Antiviral Treatments in Patients with Hepatitis B

    Jun 1, 2023, 00:00

  • EE98 Health Economic Evaluation of COVID-19 Vaccines: A Systematic Literature Review

    Jun 1, 2023, 00:00

  • HSD47 Predictors of Initial Antihypertensive Intensity in Newly-Treated Hypertension Patients with Hypertension

    Jun 1, 2023, 00:00

  • EPH80 Predicting Anxiety and Depression in the First Year Following Breast Cancer Diagnosis Using a Large Administrative Claims Data

    Jun 1, 2023, 00:00

  • Disclosure Information

    Jun 1, 2023, 00:00

  • EE361 Economic Evaluation of Screen-and-Treat Strategies for Asymptomatic Helicobacter Pylori Infection in China

    Jun 1, 2023, 00:00

  • EE120 Assessing the Potential Cost Effectiveness of Cell Therapy Adjuvant to Surgery for Hirschsprung Disease

    Jun 1, 2023, 00:00

  • EPH166 The Effect of COVID-19 on Maternal and Neonatal Outcomes in a Large Tertiary Health System in Saudi Arabia

    Jun 1, 2023, 00:00

  • HPR20 Are We Ready for Reimbursement of Software As a Medical Device in Asia-Pacific (APAC) Region?

    Jun 1, 2023, 00:00

  • EPH213 Understanding the Relationship between Socioeconomic Disadvantage Ranking and Access to Aortic Valve Procedures

    Jun 1, 2023, 00:00

  • MSR63 Analysis of Rare Events in Outcomes Research Using Department of Defense Data: Intravenous Immune Globulin Therapy for Bulluous Pemphiogoid

    Jun 1, 2023, 00:00

  • EE341 Cost Effectiveness of Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia in Mexico

    Jun 1, 2023, 00:00

  • EE489 The Economic Burden of Caring for a Child with Duchene Muscular Dystrophy in Canada: A Caregiver Survey

    Jun 1, 2023, 00:00

  • EE274 Is It Worthwhile for an Orphan Product to Expand Indications Given the Risk of Medicare Negotiation?

    Jun 1, 2023, 00:00

  • MT7 Hospital Waste and Cost Prevention Potential of Reprocessing Medical Devices

    Jun 1, 2023, 00:00

  • EE78 Budget Impact Analysis of Proactive Therapeutic Drug Monitoring for Inflammatory Bowel Disease Patients in the United States on Infliximab Therapy

    Jun 1, 2023, 00:00

  • PCR30 The Burden of Familial Chylomicronemia Syndrome (FCS) in Brazilian Patients – A Pilot Qualitative Study

    Jun 1, 2023, 00:00

  • EE388 Marginal Health Care Expenditures Burden for Breast Cancer Patients: A Medical Expenditure Panel Survey Study

    Jun 1, 2023, 00:00

  • EPH35 Comorbidities in Elderly Patients with Oral Corticosteroid-Dependent Asthma in South Korea

    Jun 1, 2023, 00:00

  • CO107 Physical Therapy Versus Watchful Waiting for the Treatment of Adhesive Capsulitis of the Shoulder: A Prospective Randomized Controlled Trial

    Jun 1, 2023, 00:00

  • PCR132 Symptoms and Impacts of Transfusion-Dependent Beta-Thalassemia: A Qualitative Interview Study and the Development of a Conceptual Model

    Jun 1, 2023, 00:00

  • EE314 Analysis of Factors Influencing Originator Market Share Following Biosimilar Competition

    Jun 1, 2023, 00:00

  • PCR22 Treatment Preferences Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the United States

    Jun 1, 2023, 00:00

  • HTA15 Beyond Value Assessment: Payer Perceptions of ICER’s Policy Initiatives

    Jun 1, 2023, 00:00

  • CO204 Primary and Secondary Endpoints Used in Recent (2022) Alzheimer’s Disease (AD) Phase III Clinical Trials

    Jun 1, 2023, 00:00

  • EPH207 Factors Associated with COVID-19 Infections and Deaths in the Gulf Cooperation Council (GCC) Countries: A Time Series Cross-Section Analysis

    Jun 1, 2023, 00:00

  • EE140 The Long-Term Costs and Health Impacts of Huntington’s Disease: A Novel Health Economic Modeling Framework

    Jun 1, 2023, 00:00

  • EPH226 Medical Cost and Prevalence of Mental Diseases across Different Health Insurance Systems in Japan

    Jun 1, 2023, 00:00

  • EPH235 Impact of Pharmacist-Led Interventions on Medication-Related Outcomes Among Cancer Patients: A Systematic Review

    Jun 1, 2023, 00:00

  • HSD118 Improving Healthcare Deserts in Sub-Saharan Africa: A Health Improvement Pilot Study Leveraging a Global, Cloud-Based Telemedicine Platform

    Jun 1, 2023, 00:00

  • MSR55 Identifying Treatment Patterns for Diffuse Large B-Cell Lymphoma in Real-World Data Using Unsupervised Machine Learning

    Jun 1, 2023, 00:00

  • PCR62 Post-Lockdown Behaviors and Impacts of Avoiding COVID-19 in Individuals and Caregivers of Individuals at High-Risk of Severe COVID-19: A Qualitative Study

    Jun 1, 2023, 00:00

  • CO208 Recurrence Rates and Survival Among Patients with Early-Stage Cancers: A Systematic Literature Review

    Jun 1, 2023, 00:00

  • HPR142 The Impact of Neighborhood Factors on Pediatric Ed Visits for Ambulatory Care Sensitive Conditions

    Jun 1, 2023, 00:00

  • PCR24 Measuring the Prevalence of Fatigue in Children with Cancer: Evidence from Egypt

    Jun 1, 2023, 00:00

  • EPH4 Validation of Novel Identification Algorithms for Nonfatal Myocardial Infarction Using Uniform Objective Criteria and Pooled Clinical Trial Data

    Jun 1, 2023, 00:00

  • EE365 Cost-Utility Analysis of Early Reconstruction Surgery Versus Rehabilitation and Delayed Reconstruction for Anterior Cruciate Ligament Tears in Low and Middle-Income Country

    Jun 1, 2023, 00:00

  • HTA64 Burden of Illness in Patients with Facial Angiofibroma Associated with Tuberous Sclerosis Complex: A Systematic Review

    Jun 1, 2023, 00:00

  • EE317 Examining ICER's Inclusion of Novel Value Factors: Do They Move the Needle on Value Appraisals?

    Jun 1, 2023, 00:00

  • EPH13 Trends in Mortality Related to Hepatitis C in Colombia 1997 – 2020

    Jun 1, 2023, 00:00

  • EPH225 Understanding the Relationship between Depression and Suicidal Tendencies Among Tertiary Students in Ghana

    Jun 1, 2023, 00:00

  • EPH109 Excess Mortality from Diabetes Mellitus in the First Year of the Pandemic in Colombia

    Jun 1, 2023, 00:00

  • PCR44 The Impact of Health Literacy on Health-Related Quality of Life: A Cross-Sectional Study in Hong Kong

    Jun 1, 2023, 00:00

  • EE384 Cost-Effectiveness of Hemithyroidectomy Versus Total Thyroidectomy for Patients with Low Risk Differentiated Thyroid Cancer

    Jun 1, 2023, 00:00

  • SA3 Characteristics of Patients Treated with CAR-T Therapies across Multiple Indications Utilizing the TriNetX Network

    Jun 1, 2023, 00:00

  • RWD45 Global Pricing Trends of Hepatitis C Medications

    Jun 1, 2023, 00:00

  • RWD112 The Medication Regimen Complexity Index Score As an Indicator of Racial Health Disparities in Clinical Outcomes

    Jun 1, 2023, 00:00

  • CO66 Real-World Study on Characteristics, Post-Nephrectomy Journey, and Outcomes of Patients with Early-Stage Renal Cell Carcinoma Based on Risk Groups

    Jun 1, 2023, 00:00

  • MT30 Medtech Innovations in Oncology: A Review of NICE Medtech Innovation Briefings from 2014 to 2022

    Jun 1, 2023, 00:00

  • EPH182 Disparities in Early Diagnosis, Treatment, and Survival Outcomes Among Patients with Early-Onset Colorectal Cancer in Texas

    Jun 1, 2023, 00:00

  • SA46 Understanding the Complexities of the Israeli Mytrial Registry

    Jun 1, 2023, 00:00

  • HPR15 Is Drug Novelty Associated with Greater Health Benefits?

    Jun 1, 2023, 00:00

  • HSD62 An Analysis of Asthma Care Pathways and Patient Outcomes in an East London Population Cohort: A Longitudinal Analysis Using Routinely Collected Data

    Jun 1, 2023, 00:00

  • PCR187 Patient and Physician Satisfaction of Treatment with Eculizumab or Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: Results from a Real-World Disease-Specific Programme

    Jun 1, 2023, 00:00

  • HPR62 Making the Cut: An Assessment of ICER’s Acceptance of Evidence in Unsupported Price Increase Reports

    Jun 1, 2023, 00:00

  • HPR112 Systematic Review for Rare Diseases Policy: A Sight in Peru and Colombia

    Jun 1, 2023, 00:00

  • PCR173 Predictors of Pediatric Emergency Department (ED) Visits for the Acute Ambulatory Care Sensitive Conditions (ACSC)

    Jun 1, 2023, 00:00

  • PCR35 Asthma Management Support Needs Among Young Adults: A Pilot Qualitative Study

    Jun 1, 2023, 00:00

  • PCR58 Comparing Adherence in Patients with Type 2 Diabetes Initiating Glucagon-like Peptide-1 Receptor Agonists or Sodium-Glucose Cotransporter-2 Inhibitors

    Jun 1, 2023, 00:00

  • PCR75 Assessment of Completion Time to Optimize the Administration of Common Patient-Reported Outcome Measures (PROMS) in Oncology Clinical Trials

    Jun 1, 2023, 00:00

  • RWD77 $0 Drug Copay Program Increases Generic Drug Use Among Members with Diabetes in Louisiana: Six-Month Outcomes Analysis

    Jun 1, 2023, 00:00

  • EE315 Trends in Medical Expenditure and Resource Utilization Among Opioid, Benzodiazepine, Skeletal Muscle Relaxant, and Gabapentin Users: A Pooled Cross Sectional Analysis from 2009 - 2019

    Jun 1, 2023, 00:00

  • EPH261 How Does Private Health Insurance Supplement Public Health Insurance and Encourage Preventive Care Usage?: A Longitudinal Study in Australia

    Jun 1, 2023, 00:00

  • PCR210 Adaptive Choice Based Conjoint Contribution to the Elicitation of Patients’ Preferences and Shared Decision-Making Process for the Pharmaceutical Treatment for Osteoarthritis

    Jun 1, 2023, 00:00

  • CO209 Association between Baseline Bone Mineral Density Testing and the Risk of Fractures in Men Initiating Androgen Deprivation Therapy: Population-Based Study

    Jun 1, 2023, 00:00

  • CO151 Impact of the Rational Antibiotic Use System on Hospital Performance at Cartagena Colombia from 2018 to 2021

    Jun 1, 2023, 00:00

  • HTA102 Early Scientific Advice in Europe: An Overview of Processes and Requirements

    Jun 1, 2023, 00:00

  • CO22 Tools for Assessing Therapeutic Progress in Patients with Rett Syndrome

    Jun 1, 2023, 00:00

  • HPR90 Sustainability of Biosimilars Medicines Policies in Brazil

    Jun 1, 2023, 00:00

  • HPR82 How Has Commercial Coverage of Specialty Drugs Changed over Time?

    Jun 1, 2023, 00:00

  • HPR10 The Desirability of Implementing an Outcome-Based Delayed Payment Model for Autologous Gene Therapy Atidarsagene Autotemcel (LIBMELDY®)

    Jun 1, 2023, 00:00

  • EE498 Economic Evaluation of Nanoparticle Albumin-Bound paclitaxel for Previously Treated Advanced NSCLC in Japan

    Jun 1, 2023, 00:00

  • RWD180 What Does Healthcare Resource Utilization Look like in the General Population of the US? A Real-World Analysis Using Claims Data

    Jun 1, 2023, 00:00

  • CO170 Baseline Characteristics, Including Hospitalizations, of Asthma Patients Treated with Dupilumab in the Real World: The Rapid Registry

    Jun 1, 2023, 00:00

  • HTA57 Quantifying Heterogeneity within and between Treatment Guidelines for Type 2 Diabetes: Potential Implications for EU-Wide Health Technology Assessment

    Jun 1, 2023, 00:00

  • PCR73 Health-Related Quality of Life and Economic Burden in Chinese Patients with Cutaneous T-Cell Lymphoma (CTCL) – Results from Interim Analysis

    Jun 1, 2023, 00:00

  • RWD11 Occurrence and Severity of Depression, Antidepressant Use Among Alzheimer’s Disease (AD) Patients across Race/Ethnicity

    Jun 1, 2023, 00:00

  • EE351 Comparing Real-Time Continuous Glucose Monitoring with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes on Insulin Therapy: A Cost-Utility Study

    Jun 1, 2023, 00:00

  • EE308 Estimated Annual Costs Among Patients with Activated PI3K Delta Syndrome

    Jun 1, 2023, 00:00

  • PCR130 Beliefs Regarding Patient Experience in the Emergency Department Among Individuals Living with Sickle Cell Disease

    Jun 1, 2023, 00:00

  • PCR117 Meaningful Change Thresholds in Patient-Reported Outcome Scores for Patients with Colorectal Cancer – A Systematic Literature Review

    Jun 1, 2023, 00:00

  • EE321 Cost Impact of Next Generation Sequencing Testing in NSCLC with and without RNA Sequencing

    Jun 1, 2023, 00:00

  • RWD74 Up to New Limits: The Number of Petaflops Necessary for Realistic Health Economic Models

    Jun 1, 2023, 00:00

  • PCR230 Estimating Utility Values Using the Duchenne Muscular Dystrophy-Quality of Life Measure (DMD-QOL): A New Preference-Based Measure for Duchenne Muscular Dystrophy

    Jun 1, 2023, 00:00

  • RWD19 Comparative Effectiveness Using External Controls for Single-Arm Trials of Pembrolizumab in Tumor-Agnostic Indications Leveraging Real-World Data

    Jun 1, 2023, 00:00

  • HPR91 The State of Cost-Effectiveness Analyses on Health Services and Procedures

    Jun 1, 2023, 00:00

  • MT36 Cancer Biomarkers from a Technological Perspective: Past, Present, or Future?

    Jun 1, 2023, 00:00

  • EE387 Cost of Non-Melanoma Skin Cancer Care in the U.S.- An Analysis from Medicare Population

    Jun 1, 2023, 00:00

  • HPR129 Is Cost-Effectiveness Analysis a Tool to Exercise Value-Based Pricing or Monopsony Power? Evidence from Canada and Other Countries

    Jun 1, 2023, 00:00

  • EE260 Cost-Effectiveness Analysis of Sacituzumab Govitecan As Second-Line Treatment for Metastatic Triple-Negative Breast Cancer in Japan

    Jun 1, 2023, 00:00

  • EE107 Cost-Effectiveness of Mechanical Thrombectomy for Acute Ischemic Stroke: Colombian Health System Perspective

    Jun 1, 2023, 00:00

  • EPH130 Association of Lynch Syndrome with Skin Cancer: An Exploratory Analysis Using Claims Data

    Jun 1, 2023, 00:00

  • HTA26 Duration and Timing of Treatment Waning: Determining the Start and Stop Points Using Pembrolizumab in NSCLC As a Case Study

    Jun 1, 2023, 00:00

  • RWD98 Understanding the Role of Real-World Evidence for Reimbursement and Market Access of Ultra Orphan Drugs: Insights and Lessons from Case Studies of NICE Highly Specialized Technology (HST) Assessment Reports

    Jun 1, 2023, 00:00

  • PCR165 Translation and Cultural Adaptation of the Essential Tremor Embarrassment Assessment (ETEA) Questionnaire to the Romanian Population

    Jun 1, 2023, 00:00

  • HPR118 Examining Non-Price Determinants of Regional Pharmaceutical Expenditures-a Case of Burkina Faso

    Jun 1, 2023, 00:00

  • EPH230 Estimating Risk of Disease Progression from Mild Cognitive Impairment (MCI) to Alzheimer’s Disease (AD) Using Administrative Claims

    Jun 1, 2023, 00:00

  • EE282 Financial Burden of Progression of Chronic Myeloid Leukemia (CML) Patients Who Failed Two or More Tyrosine Kinase Inhibitors Treatment in the Brazilian Private Market Perspective

    Jun 1, 2023, 00:00

  • HSD83 Hypertension and Pregnancy: Pharmacologic Treatment and Pregnancy Outcomes

    Jun 1, 2023, 00:00

  • EE329 The Value-Based Price for a Bivalent COVID-19 Booster Vaccine in the United Kingdom

    Jun 1, 2023, 00:00

  • HPR70 Therapeutic Preference for Alzheimer’S Disease Treatments: A Discrete Choice Experiment (DCE) with Caregivers and Neurologists

    Jun 1, 2023, 00:00

  • PCR16 Patient-Reported Outcomes in Opioid Use Disorder (PR-OUD): Recommendations and Barriers in Clinical Trials and Studies

    Jun 1, 2023, 00:00

  • Economic Evaluations of Rare Diseases

    Jun 1, 2023, 00:00

  • EPH192 Association of Long COVID with Seeing Difficulties Among Adults in the United States

    Jun 1, 2023, 00:00

  • HPR120 The Pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A Comparative Study Using Donabedian's Structure-Process-Outcome Framework

    Jun 1, 2023, 00:00

  • P11 Depression Severity Among Patients with Psychiatric Disorders during the COVID-19 Pandemic

    Jun 1, 2023, 00:00

  • EE97 Optimal Gonorrhea Control through Vaccination and Screening: A Mathematical Modeling and Cost-Effectiveness Study

    Jun 1, 2023, 00:00

  • RWD10 Risk of Depression before Alzheimer’s Disease Diagnosis and Hyperlipidemia Using Real-World Data

    Jun 1, 2023, 00:00

  • EE30 Annual Disability-State Transition Probabilities Estimated from a Large Sample (>6000) of Australians with Multiple Sclerosis from MS-Base

    Jun 1, 2023, 00:00

  • HPR125 Descriptive Study Investigating Impact of Transition to Universal Health Insurance Coverage on Utilization of Healthcare in Sudan, 2016 - 2021

    Jun 1, 2023, 00:00

  • RWD102 Cluster Algorithm for Credible Subgroup Identification in Patients with Erectile Dysfunction Receiving Tadalafil: A Real-World Data Study

    Jun 1, 2023, 00:00

  • EE115 Nash Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis from a Natural History Cohort in the US

    Jun 1, 2023, 00:00

  • EE58 Healthcare Resource Utilization Among Patients with Transfusion-Dependent Beta-Thalassemia in Italy

    Jun 1, 2023, 00:00

  • PCR188 Assessing Patient Preference for Verbal Descriptor Scales

    Jun 1, 2023, 00:00

  • MSR40 Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results

    Jun 1, 2023, 00:00

  • EE345 Strengths and Limitations of Different Costing Approaches Used for Hospital Budget Impact Models: Application to Imaging Guidance in Left Atrial Appendage Occlusion Procedures

    Jun 1, 2023, 00:00

  • EE88 Cost-Effectiveness Analysis of Etodolac and Aceclofenac in Low Back Pain

    Jun 1, 2023, 00:00

  • EE216 Which Modelling Methods Can Account for Additional Value Elements in HTAs? Results from a Pragmatic Review

    Jun 1, 2023, 00:00

  • RWD16 Laparoscopic Surgery for Adrenocortical Carcinoma: Estimating the Risk of Margin-Positive Resection

    Jun 1, 2023, 00:00

  • PCR83 Defining the Smallest Worthwhile Effect of Treatment for Progressive Nervous System Tumors in People with NF2-Related Schwannomatosis: Qualitative Patient Interview Results from a Multicenter Clinical Trial

    Jun 1, 2023, 00:00

  • PCR166 PRO Reporting and Methodological Rigor in NSCLC RCTs, a Cause for Concern

    Jun 1, 2023, 00:00

  • EPH163 Association of Weight Loss Agents with the Risk of Abnormal Liver Function: A Population-Based Cross-Sectional Study

    Jun 1, 2023, 00:00

  • EE528 Healthcare Resource Utilization Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in England

    Jun 1, 2023, 00:00

  • HTA20 Deconstructing ICER Value Assessments: Which Components Do Payers Value Most?

    Jun 1, 2023, 00:00

  • P50 Using Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Chronic Myeloid Leukemia Patients Who Are in Remission

    Jun 1, 2023, 00:00

  • EE92 Economic Impact of Pencil Point Spinal Needles Versus Conventional Cutting Needles on Postdural Puncture Headache

    Jun 1, 2023, 00:00

  • EE217 Efficiency-Equity Trade-Offs in Cost-Effectiveness Analyses: An Umbrella Review of Previous Systematic Literature Reviews

    Jun 1, 2023, 00:00

  • P2 Economic Evaluation of Exagamglogene Autotemcel (EXA-CEL) Gene-Edited Therapy in Patients with Transfusion-Dependent Beta-Thalassemia

    Jun 1, 2023, 00:00

  • RWD38 Quality of Electronic Health Records: Managing Aggregated Patient Demographic Information

    Jun 1, 2023, 00:00

  • HPR78 A Comparison of Orphan Drugs Approved By the FDA and EMA, 1995-2022

    Jun 1, 2023, 00:00

  • EE12 Diagnosing Irritable Bowel Syndrome (IBS): A Real-World Study to Assess Resource Utilization

    Jun 1, 2023, 00:00

  • EE125 Economic Evaluations of Pharmacological Treatments for Active Tuberculosis: A Systematic Review

    Jun 1, 2023, 00:00

  • MT52 Real World Utilization of Digital Therapeutics: A Review

    Jun 1, 2023, 00:00

  • CO149 Prevalence of Chain-of-Event and Contributing Conditions Among Treated COVID-19 Patients in the United States: Identifying Risk Factors Associated with Deaths

    Jun 1, 2023, 00:00

  • PCR118 Quantifying Patient Preferences for Targeted Therapies in Metastatic Melanoma: A Discrete-Choice Experiment

    Jun 1, 2023, 00:00

  • EPH160 Racial/Ethnic Differences in the Use of Angiotensin II Receptor Stimulatory Vs. Inhibitory Antihypertensive Among US Adults with Hypertension

    Jun 1, 2023, 00:00

  • OP10 Safety Monitoring of Orphan Drugs Project: SFDA Experience

    Jun 1, 2023, 00:00

  • EE276 Economic Evaluation of Trifluridine and Tipiracil Hydrochloride in the Treatment of Metastatic Gastric Cancer in the Brazilian Private Health Care Sector

    Jun 1, 2023, 00:00

  • P7 Racial and Ethnic Differences in the Use and Discontinuation of Long-Acting Injectable Antipsychotics

    Jun 1, 2023, 00:00

  • PCR115 Adherence to Disease-Modifying Treatments in Patients with Active and Nonactive Progressive Multiple Sclerosis in the United States

    Jun 1, 2023, 00:00

  • PCR93 Effect of Physicians’ Prescribing Choices of First- or Second-Line Tumor Necrosis Factor Inhibitor Biologics Versus Non-Tumor Necrosis Factor Inhibitor Biologic Therapies on Psoriatic Arthritis Patient-Reported Outcomes

    Jun 1, 2023, 00:00

  • CO12 Evaluation of Hyponatremia Risk Among Geriatric Patients Exposed to Selective Serotonin Reuptake Inhibitors (SSRIS) and Thiazide Diuretics

    Jun 1, 2023, 00:00

  • RWD129 Work, Productivity, and Activity Impairment in Patients with Immunoglobulin a Nephropathy: Results from a Real-World Study

    Jun 1, 2023, 00:00

  • SA51 Severity Diagnosis and Neuropsychological Test Result from Clinical Notes Among Veterans with Alzheimer's Disease

    Jun 1, 2023, 00:00

  • HSD64 Biologics Vs. Biosimilars Utilization Among Rheumatoid Arthritis (RA) Patients

    Jun 1, 2023, 00:00

  • MT24 Health Technologies Aimed at the Aging Population Are Not a Global Concern

    Jun 1, 2023, 00:00

  • P56 Comparison of Methods for Incorporating Time-to-Event Outcomes in Budget Impact Analyses

    Jun 1, 2023, 00:00

  • RWD181 Healthcare Resource Utilization and Economic Burden of Hidradenitis Suppurativa in the USA Using Marketscan Claims Data

    Jun 1, 2023, 00:00

  • EE331 Leveraging Time-Use Data to Estimate Market and Non-Market Productivity Losses Due to Respiratory Syncytial Virus (RSV) Disease Among Adults Aged ≥60 Years in the United States (US)

    Jun 1, 2023, 00:00

  • PCR159 The Clinical and Financial Impact of Blue Cross and Blue Shield of Louisiana Waiving Cost Share for the First Mental Health and Substance Use Disorder Follow-up Visit

    Jun 1, 2023, 00:00

  • P18 A Review of HTA Guidelines on Societal and Novel Value Elements

    Jun 1, 2023, 00:00

  • PCR86 Using Qualitative Methods to Develop Grounded Relevant Content for Preference Surveys in a Specific Rare Bleeding Disorder (SRBD)

    Jun 1, 2023, 00:00

  • PCR249 Advancing Equity, Diversity, Inclusion, and Belonging in Patient Centered Drug Development with Patient Preference Research

    Jun 1, 2023, 00:00

  • SA12 Use of Living Systematic Reviews (LSRS) Beyond COVID-19

    Jun 1, 2023, 00:00

  • P20 An Evaluation of Special Considerations in the Assessment and Decision-Making Processes across HTA Agencies for Drugs for Rare Diseases

    Jun 1, 2023, 00:00

  • P15 Indirect Treatment Comparisons of Time-to-Event Outcomes with Mis-Matched "Time Zero": Methodology and Application in Resectable Non-Small Cell Lung Cancer

    Jun 1, 2023, 00:00

  • MSR81 Vaccine Rate Coverage Forecast in Brazil: Is It Possible to Keep Polio Eradicated?

    Jun 1, 2023, 00:00

  • EE122 The Economic Impact of a Psychosocial Utility Benefit Associated with Pre-Exposure Prophylaxis (PrEP) for COVID-19, in Immunocompromised (IC) Individuals – a Case Study for Future PrEP Evaluations

    Jun 1, 2023, 00:00

  • CO226 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Multiple Myeloma in the US: Real-World Evaluation of Patient Characteristics and Treatment Patterns

    Jun 1, 2023, 00:00

  • HSD35 If Primary Prevention Is the Solution, Why Don't We Take Advantage of All Opportunities in Brazil?

    Jun 1, 2023, 00:00

  • EE171 Time to Diagnosis and Cost Effectiveness of Whole Exome Sequencing (WES) Position in the Diagnostic Pathways of Patients with Suspected Rare Genetic Disease

    Jun 1, 2023, 00:00

  • HPR49 The Inflation Reduction Act Exclusion Effect: An Analysis of Inflation Reduction Act Minimum-Discount Negotiation Rules

    Jun 1, 2023, 00:00

  • EPH257 Public Health Impact of UK COVID-19 Booster Vaccination during Omicron Predominance

    Jun 1, 2023, 00:00

  • SA41 Evolving Payer Perception on Patient Centricity and Real-World Eviden Insights from a Quantitative Survey

    Jun 1, 2023, 00:00

  • EE17 Societal Cost of Racial Disparities in Pneumococcal Disease in U.S. Adults Aged 50 Years or Older

    Jun 1, 2023, 00:00

  • EE99 Cost-Utility Analysis of 13-Valent Pneumococcal Conjugate Vaccine in the Immunization of Children Under Five Years for the Prevention of Invasive Pneumococcal Disease and Pneumonia in the Brazilian Public Healthcare System

    Jun 1, 2023, 00:00

  • MT49 Watch on the Dash – A CEA Tool of LAAC for Atrial Fibrillation in the Brazilian Healthcare System

    Jun 1, 2023, 00:00

  • MSR4 Rasch Calibration of the 18-Item Multidimensional Health Locus of Control - Form B Scale

    Jun 1, 2023, 00:00

  • EE139 Cost-Effectiveness of Aducanumab Versus Donepezil for Patients with Early Alzheimer's Disease

    Jun 1, 2023, 00:00

  • PCR21 Patient-Reported Outcomes to Support Regulation, Reimbursement and Health Policy Among Patients with Head and Neck Cancers: A Systematic Review

    Jun 1, 2023, 00:00

  • EE306 The Burden of Disease of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Costa Rica

    Jun 1, 2023, 00:00

  • HPR39 A Time-to-Event Framework for Quantifying Clinical Significance of Effect in Alzheimer’s Disease Clinical Trials

    Jun 1, 2023, 00:00

  • HPR5 Minimally Invasive Thyroidectomy Implementation for Cancer Care: Do Racial, Ethnic and Insurance Characteristics Play a Role?

    Jun 1, 2023, 00:00

  • CO46 Determining Patient-Reported Outcomes Fit-for-Purpose By Cross-Linking Regulatory Perspective and Descriptive Information in Interconnected Databases

    Jun 1, 2023, 00:00

  • HTA59 Anticipating Market Access Challenges in Canada for Lecanemab: Learnings from Previous Health Technology Assessments of Disease-Modifying Therapies in Neurodegenerative Diseases

    Jun 1, 2023, 00:00

  • CO159 Treatment Characteristics of Adults with Hepatocellular Carcinoma after Curative Resection or Ablation: A Multinational, Retrospective Chart Review Study

    Jun 1, 2023, 00:00

  • MSR87 Reviewing Elements to Inform Re-Running Searches: Refreshing Systematic Literature Reviews

    Jun 1, 2023, 00:00

  • HSD99 Telemedicine and the Utilization of Outpatient Mental Health Services By Patients with Incident Major Depressive Disorder during the COVID-19 Pandemic

    Jun 1, 2023, 00:00

  • HPR3 Why the Increase? Drilling Down on Increases in Prescribed Medication Expenditures in the United States between 2011 and 2020: Findings from the Medical Expenditures Panel Survey

    Jun 1, 2023, 00:00

  • EE196 Impact of Inclusion of Finerenone in the Burden of Disease of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D) in Ecuador

    Jun 1, 2023, 00:00

  • OP5 Cost-Shifting Practices in Hospitals: A Systematic Review

    Jun 1, 2023, 00:00

  • EE518 Characteristics of the Clinical Pharmacist Interventions at a Tertiary Cancer Care Hospital in Qatar

    Jun 1, 2023, 00:00

  • CO45 Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults with Chronic Plaque Psoriasis from a 52-Week, Phase 2 Open-Label Safety Trial

    Jun 1, 2023, 00:00

  • EE3 Cost Estimation of Published Heart Failure and Edema Events in Hyperkalemic Patients on Patiromer and Sodium Zirconium Cyclosilicate

    Jun 1, 2023, 00:00

  • MT39 Incremental Costs of New Permanent Pacemaker Implantation after Transcatheter Aortic Valve Replacement (TAVR)

    Jun 1, 2023, 00:00

  • RWD79 Relationship between Body Mass Index and Diagnosis of Overweight or Obesity in Veteran’s Administration Population

    Jun 1, 2023, 00:00

  • P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims

    Jun 1, 2023, 00:00

  • PCR114 Utilizing Time-Driven Activity Based Costing to Explore Variation in the Value of Hip Arthroscopy for Acetabular Labral Repair

    Jun 1, 2023, 00:00

  • EE428 Economic Value of a Novel Macrophage-Regulating Treatment for Diabetic Foot Ulcers from a Healthcare Sector Perspective

    Jun 1, 2023, 00:00

  • EE357 Implementing the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach – A Case Example in HCV Therapies

    Jun 1, 2023, 00:00

  • MT37 An Analysis of US Urologists Performing Outpatient-Based Inflatable Penile Prosthesis Implantation

    Jun 1, 2023, 00:00

  • HTA93 A Systematic Literature Review on Incorporating Equity Considerations in Health Technology Assessment (HTA)

    Jun 1, 2023, 00:00

  • EE411 Menopausal Women at Work: The Measured and Unmeasured Impact of Symptoms on Productivity

    Jun 1, 2023, 00:00

  • RWD168 Annual Transition Probabilities for Disease Severity Changes in an Australian Cohort of People with Idiopathic Pulmonary Fibrosis

    Jun 1, 2023, 00:00

  • EE356 Health Care Resource Use and Medical Costs Attributable to Respiratory Syncytial Virus (RSV) Among Adults ≥60 Years of Age in the United States: A Retrospective Claims Database Analysis

    Jun 1, 2023, 00:00

  • CO193 Replication of Mini-Sentinel Saxagliptin Study Assessing Acute Myocardial Infarction Using Electronic Medical Record Network

    Jun 1, 2023, 00:00

  • SA74 Decentralized Clinical Trials and Time Burden: Important Considerations for Potential Clinical Trial Participants

    Jun 1, 2023, 00:00

  • EPH264 Differences in Concussion Diagnosis By Sex and Age Group in a General Population

    Jun 1, 2023, 00:00

  • CO175 Acute Kidney Injury from Intravitreal Anti–Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-Analysis

    Jun 1, 2023, 00:00

  • RWD61 Comparison of Healthcare Costs for Women with Treated Vs Untreated Vasomotor Symptoms Associated with Menopause

    Jun 1, 2023, 00:00

  • EE382 Healthcare Expenditure Burden of Melanoma in the Era of Immune Checkpoint Inhibitors

    Jun 1, 2023, 00:00

  • MT50 Value Stream Mapping and Analysis of the Quality Parameters from the Control Units Processed Using a Semi-Automated, Buffy Coat Method, in a Colombian Blood Bank Center

    Jun 1, 2023, 00:00

  • Editorial Board

    May 1, 2023, 08:40

  • Caregiving-Related Work Productivity Loss Among Employed Family and Other Unpaid Caregivers of Older Adults

    May 1, 2023, 00:00

  • Comparability Among Modes of Data Collection for Patient-Reported Outcome Measures: Opening the Gates for Faithful Migration

    May 1, 2023, 00:00

  • Health and Economic Evaluation of Vaccination Against Pertussis in China: A 40-Year Analysis

    May 1, 2023, 00:00

  • The European Organisation for Research and Treatment of Cancer Quality of Life Utility-Core 10 Dimensions: Development and Investigation of General Population Utility Norms for Canada, France, Germany, Italy, Poland, and the United Kingdom

    May 1, 2023, 00:00

  • Cost-Effectiveness of Medication Therapy Management Program Across Racial and Ethnic Groups Among Medicare Beneficiaries [Editor's Choice]

    May 1, 2023, 00:00

  • Twenty-Five Years of Health Economics and Outcomes Research: An Exploration of Value in Health

    May 1, 2023, 00:00

  • Economic Evaluation of Elective Cesarean Section on Maternal Request Compared With Planned Vaginal Birth—Application to Swedish Setting Using National Registry Data

    May 1, 2023, 00:00

  • Economic Evaluation of Family-Focused Programs When Parents Have a Mental Health Problem: Methodological Considerations

    May 1, 2023, 00:00

  • Table of Contents

    May 1, 2023, 00:00

  • Copyright/Subscription

    May 1, 2023, 00:00

  • Developing Prioritization Criteria to Identify Target Drugs for CalRx, the California Generic Drugs Initiative

    May 1, 2023, 00:00

  • The Impact of Reimbursement for Non-Face-to-Face Chronic Care Management on Health Utilization Among Patients With Type 2 Diabetes in Louisiana

    May 1, 2023, 00:00

  • The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes: A Cluster Randomized Trial-Based Economic Evaluation

    May 1, 2023, 00:00

  • Censoring Time Trade-off Values at 0 Versus at −1: How Does the Assumption for Worse-Than-Dead Time Trade-off Values Affect the Modeling of EQ-5D-5L Valuation Data?

    May 1, 2023, 00:00

  • EQ-5D-3L Norms for the European Older Population: Country-Specific Norms for 15 European Countires Based on the Survey of Health, Ageing, and Retirement in Europe

    May 1, 2023, 00:00

  • Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review

    May 1, 2023, 00:00

  • Updated Recommendations on Evidence Needed to Support Measurement Comparability Among Modes of Data Collection for Patient-Reported Outcome Measures: A Good Practices Report of an ISPOR Task Force

    May 1, 2023, 00:00

  • Dealing With Uncertainty in Early Health Technology Assessment: An Exploration of Methods for Decision Making Under Deep Uncertainty [Editor's Choice]

    May 1, 2023, 00:00

  • Do Misconceptions About Health-Related Quality of Life Affect General Population Valuations of Health States? [Editor's Choice]

    May 1, 2023, 00:00

  • Estimating Joint Health State Utility Algorithms Under Partial Information

    May 1, 2023, 00:00

  • Assessing Outcomes for Cost-Utility Analysis in Children and Adolescents With Mental Health Problems: Are Multiattribute Utility Instruments Fit for Purpose?

    May 1, 2023, 00:00

  • The Use of Multicriteria Decision Analysis to Support Decision Making in Healthcare: An Updated Systematic Literature Review [Editor's Choice]

    May 1, 2023, 00:00

  • Editorial Board

    Apr 20, 2023, 10:47

  • Editorial Board

    Apr 2, 2023, 08:18

  • Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View

    Apr 1, 2023, 00:00

  • Reducing Hospital Capacity Needs for Seasonal Respiratory Infections: The Case of Switching to High-Dose Influenza Vaccine for Dutch Older Adults

    Apr 1, 2023, 00:00

  • Table of Contents

    Apr 1, 2023, 00:00

  • Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers

    Apr 1, 2023, 00:00

  • Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised [EDITOR'S CHOICE]

    Apr 1, 2023, 00:00

  • Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making

    Apr 1, 2023, 00:00

  • EUreccA 2025: A Multistakeholder Effort to Further Real-World Evidence in Healthcare Decision Making

    Apr 1, 2023, 00:00

  • Approaches to the Assessment of Clinical Benefit of Treatments for Conditions That Have Heterogeneous Symptoms and Impacts: Potential Applications in Rare Disease

    Apr 1, 2023, 00:00

  • Table of Contents

    Apr 1, 2023, 00:00

  • A Conceptual Framework for Life-Cycle Health Technology Assessment

    Apr 1, 2023, 00:00

  • Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward

    Apr 1, 2023, 00:00

  • Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies

    Apr 1, 2023, 00:00

  • Author Reply

    Apr 1, 2023, 00:00

  • Reviewer Acknowledgment

    Apr 1, 2023, 00:00

  • The Real-World Evidence Workstream in EUreccA 2025: How the Task Was Addressed

    Apr 1, 2023, 00:00

  • Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study

    Apr 1, 2023, 00:00

  • Copyright/Subscription

    Apr 1, 2023, 00:00

  • Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping

    Apr 1, 2023, 00:00

  • Suitability of Preference Methods Across the Medical Product Lifecycle: A Multicriteria Decision Analysis

    Apr 1, 2023, 00:00

  • Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification

    Apr 1, 2023, 00:00

  • Interaction Effects in Health State Valuation Studies: An Optimal Scaling Approach

    Apr 1, 2023, 00:00

  • Mapping Studies to Estimate Health-State Utilities From Nonpreference-Based Outcome Measures: A Systematic Review on How Repeated Measurements are Taken Into Account [EDITOR'S CHOICE]

    Apr 1, 2023, 00:00

  • An Analysis of Accessibility of Representative Psychotropic Medicine From the World Health Organization Model List of Essential Medicines in Developing Countries With Different Income Levels

    Apr 1, 2023, 00:00

  • Between-Hospital and Between-Physician Variation in Outcomes and Costs in High- and Low-Complex Surgery: A Nationwide Multilevel Analysis

    Apr 1, 2023, 00:00

  • A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma

    Apr 1, 2023, 00:00

  • Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force [EDITOR'S CHOICE]

    Apr 1, 2023, 00:00

  • Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis

    Apr 1, 2023, 00:00

  • Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study

    Apr 1, 2023, 00:00

  • Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Step Forward [EDITOR'S CHOICE]

    Apr 1, 2023, 00:00

  • Editorial Board

    Mar 2, 2023, 08:26

  • The Value of Medical Innovation Versus Industry Rewards

    Mar 1, 2023, 00:00

  • Equitable Prioritization of Health Interventions by Incorporating Financial Risk Protection Weights Into Economic Evaluations [Editor's Choice]

    Mar 1, 2023, 00:00

  • Drug Pricing Throughout the Product Lifecycle: A Work in Progress [Editor's Choice]

    Mar 1, 2023, 00:00

  • Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review

    Mar 1, 2023, 00:00

  • Cost-Effectiveness of First-Line Pembrolizumab Monotherapy Versus Chemotherapy in High Programmed Death-Ligand 1 Advanced Non–Small Cell Lung Cancer in the Irish Healthcare Setting

    Mar 1, 2023, 00:00

  • Author Reply

    Mar 1, 2023, 00:00

  • Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions [Editor's Choice]

    Mar 1, 2023, 00:00

  • The Influence of US Drug Price Dynamics on Cost-Effectiveness Analyses of Biologics

    Mar 1, 2023, 00:00

  • Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the “Age of Cures” and Their Implications for Dynamic Efficiency [Editor's Choice]

    Mar 1, 2023, 00:00

  • Table of Contents

    Mar 1, 2023, 00:00

  • Modeling Tiered Pricing Frameworks: A Simulation Approach

    Mar 1, 2023, 00:00

  • Measuring Health and Well-Being: We Need to Get it Right for Patients, With Patients

    Mar 1, 2023, 00:00

  • The Impact on Cost-Effectiveness of Accounting for Generic Drug Pricing: Four Case Studies [Editor's Choice]

    Mar 1, 2023, 00:00

  • Copyright/Subscription

    Mar 1, 2023, 00:00

  • How Much Does the US Public Value Equity in Health? A Systematic Review

    Mar 1, 2023, 00:00

  • Innovative Public Price Mechanisms for Market Access of Innovative Medicines: A Marriage Between Cost-Effectiveness, Medical Need, and Budget Impact

    Mar 1, 2023, 00:00

  • The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price

    Mar 1, 2023, 00:00

  • Does the United States Need Better Policies Governing Generic Drug Use?

    Mar 1, 2023, 00:00

  • The “Affordable Medicines” Reimbursement Program in Ukraine: Framework Assessment and Impact Evaluation

    Mar 1, 2023, 00:00

  • Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone

    Mar 1, 2023, 00:00

  • The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom

    Mar 1, 2023, 00:00

  • Editorial Board

    Feb 7, 2023, 10:35

  • Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years

    Feb 1, 2023, 00:00

  • Preferences for Sexually Transmitted Infection and Cancer Vaccines in the United States and in China

    Feb 1, 2023, 00:00

  • The Impact of Sharing Drug Rebates at the Point of Sale on Out-of-Pocket Payments for Enrollees in Employer-Sponsored Insurance

    Feb 1, 2023, 00:00

  • Table of Contents

    Feb 1, 2023, 00:00

  • Disease-Related Loss to Government Funding: Longitudinal Analysis of Individual-Level Health and Tax Data for an Entire Country

    Feb 1, 2023, 00:00

  • Can Observational Analyses of Routinely Collected Data Emulate Randomized Trials? Design and Feasibility of the Observational Patient Evidence for Regulatory Approval Science and Understanding Disease Project

    Feb 1, 2023, 00:00

  • Modifying the Composite Time Trade-Off Method to Improve Its Discriminatory Power

    Feb 1, 2023, 00:00

  • A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force [Editor's Choice]

    Feb 1, 2023, 00:00

  • Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib [Editor's Choice]

    Feb 1, 2023, 00:00

  • Quality-Adjusted Life Expectancy Norms for the English Population [Editor's Choice]

    Feb 1, 2023, 00:00

  • Navigating Patient-Preference Studies for Cross-Stakeholder Decision Making: A Roadmap Guides the Way

    Feb 1, 2023, 00:00

  • Generic Health-Related Quality of Life Utility Measure for Preschool Children (Health Utilities Preschool): Design, Development, and Properties

    Feb 1, 2023, 00:00

  • A Scoping Review of the Use of Machine Learning in Health Economics and Outcomes Research: Part 1—Data From Wearable Devices [Editor's Choice]

    Feb 1, 2023, 00:00

  • The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis

    Feb 1, 2023, 00:00

  • The Prader-Willi Syndrome Anxiousness and Distress Behaviors Questionnaire: Development and Psychometric Validation

    Feb 1, 2023, 00:00

  • Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework? [Editor's Choice]

    Feb 1, 2023, 00:00

  • A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies

    Feb 1, 2023, 00:00

  • Copyright/Subscription

    Feb 1, 2023, 00:00

  • Gradient Boosted Tree Approaches for Mapping European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Onto 5-Level Version of EQ-5D Index for Patients With Cancer

    Feb 1, 2023, 00:00

  • Comprehensive Score for Financial Toxicity and Health-Related Quality of Life in Patients With Cancer and Survivors: A Systematic Review and Meta-Analysis

    Feb 1, 2023, 00:00

  • Editorial Board

    Jan 9, 2023, 08:36

  • Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges [Editor's Choice]

    Jan 1, 2023, 00:00

  • Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review [Editor's Choice]

    Jan 1, 2023, 00:00

  • Patient-Reported Satisfaction, Experiences, and Preferences: Same but Different? [Editor's Choice]

    Jan 1, 2023, 00:00

  • For Me or for My Relatives? Approximating Self-Protection and Local Altruistic Motivations Underlying Preferences for Public Health Policies Using Risk Perception Metrics

    Jan 1, 2023, 00:00

  • Assessment of the Social Security Administration Death Master File for Comparative Analysis Studies of Peripheral Vascular Devices

    Jan 1, 2023, 00:00

  • Heterogeneous Preferences for Colorectal Cancer Screening in Germany: Results of a Discrete Choice Experiment

    Jan 1, 2023, 00:00

  • Patient and Caregiver Experience Decision Factors in Treatment Decision Making: Results of a Systematic Literature Review of Multiple Myeloma Decision Aids

    Jan 1, 2023, 00:00

  • Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer

    Jan 1, 2023, 00:00

  • A Data-Driven Approach to Support the Understanding and Improvement of Patients’ Journeys: A Case Study Using Electronic Health Records of an Emergency Department

    Jan 1, 2023, 00:00

  • Patient Expectations About Palliative Treatment for Symptomatic Spinal Metastases: A Qualitative Study

    Jan 1, 2023, 00:00

  • Table of Contents

    Jan 1, 2023, 00:00

  • Enhancing Patient Centricity of Real-World Data Research: An Exploratory Analysis Using the Patient Experience Mapping Toolbox

    Jan 1, 2023, 00:00

  • Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process

    Jan 1, 2023, 00:00

  • Test-Retest Reliability of EQ-5D-Y-3L Best-Worst Scaling Choices of Adolescents and Adults

    Jan 1, 2023, 00:00

  • Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases

    Jan 1, 2023, 00:00

  • Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

    Jan 1, 2023, 00:00

  • Copyright/Subscription

    Jan 1, 2023, 00:00

  • Cost-Effectiveness of a Specialized Breathlessness Service Versus Usual Care for Patients With Advanced Diseases

    Jan 1, 2023, 00:00

  • Measuring, Analyzing, and Presenting Work Productivity Loss in Randomized Controlled Trials: A Scoping Review

    Jan 1, 2023, 00:00

  • The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data [Editor's Choice]

    Jan 1, 2023, 00:00

  • CO117 Assessing the Impact of Hospital Characteristics on Outcomes of Outpatient Cardiac Procedures: An Analysis of the HCUP-NASS 2019 Database

    Dec 14, 2022, 09:50

  • CO175 Systematic Literature Review of Outcomes in Patients With Advanced Basal Cell Carcinoma (ABCC) Who Progressed on or Are Intolerant to Hedgehog Inhibitors (HHI)

    Dec 1, 2022, 00:00

  • PCR210 Quality of Life and Productivity Losses of Dysmenorrhea Patients in Korea

    Dec 1, 2022, 00:00

  • EE142 The Clinical Benefits and Costs of Potential Cervical Cancer Screening Strategies in the Czech Republic

    Dec 1, 2022, 00:00

  • HTA154 Comparing Non-Oncological Rare Condition Submissions to the National Institute for Health and Care Excellence (NICE) Versus Scottish Medicines Consortium (SMC) From 2001 to 2021

    Dec 1, 2022, 00:00

  • HTA124 Real-World Data to Inform Health Technology Assessments in England: A Review of Submissions to the National Institute for Health and Care Excellence Since 2018

    Dec 1, 2022, 00:00

  • EE248 Cost Effectiveness of Novel Antiobiotic Imipenem/Cilastatin/Relebactam in Gram Negative Infections in Greece

    Dec 1, 2022, 00:00

  • PCR136 Patient and Health Care Professional Experiences of Suboptimal Insulin Dosing

    Dec 1, 2022, 00:00

  • EE454 A Distributional Cost-Effectiveness Analysis of Screening Strategies for Ovarian Cancer

    Dec 1, 2022, 00:00

  • EE580 Costs of Chronic Kidney Failure and Diabetic Nephropathy in Turkiye

    Dec 1, 2022, 00:00

  • PCR32 Self-Reported Prevalence and Impact of Clinical Signs, Symptoms, and Events in Adults With Osteogenesis Imperfecta (OI)

    Dec 1, 2022, 00:00

  • HPR44 Innovation Value Framework - Evidence From EU-4 and UK

    Dec 1, 2022, 00:00

  • HTA114 Review of Health Technology Assessment (HTA) and Recommendations for the Introduction of Higher-Valency Pneumococcal Conjugated Vaccine (PCV) in 4 European Countries, The United-Kingdom (UK), and The United-States (US)

    Dec 1, 2022, 00:00

  • EE335 Cost-Efectiveness Analysis Between Multichambered Standarized Pediatric Parental Nutrition and Individualized Compounded Parental Nutrition, Analysis From the Mexican Public Health System Perspective

    Dec 1, 2022, 00:00

  • MT31 A Novel Medical Technology for Rapid Molecular Diagnostics (Nicking Enzyme Amplification Reaction [NEAR]) - A Systematic Literature Review, Meta-Analysis

    Dec 1, 2022, 00:00

  • EE562 Cost-Effectiveness and Budget Impact Analyses of Implementing the First Pillar of Patient Blood Management, With Intravenous (IV) Ferric Carboxymaltose (FCM), on the Turkish Healthcare System

    Dec 1, 2022, 00:00

  • HPR67 Identifying the Key Challenges in the Reimbursement of Next Generation Sequencing and Future Policy Changes in Europe Using a Web-Based Portal to Engage Payers

    Dec 1, 2022, 00:00

  • HPR19 Tax Revenue Gains and Societal Net-Monetary Benefit Associated With Implementing Lung Cancer Screening in the United Kingdom

    Dec 1, 2022, 00:00

  • EPH182 Inpatient Burden of Respiratory Syncytial Virus in Children ≤2 Years of Age in Germany: A Retrospective Analysis of Nationwide Hospitalization Data, 2019-2021

    Dec 1, 2022, 00:00

  • PCR63 Using Patient Preference to Inform Ritlecitinib Dose Selection for Alopecia Areata Treatment

    Dec 1, 2022, 00:00

  • EE12 Cost of Stroke Management in Turkey

    Dec 1, 2022, 00:00

  • EE621 Cost of Illness of Vaccine-Preventable Diseases in France

    Dec 1, 2022, 00:00

  • PCR101 Understanding the Burden of Disease for Pediatric and Adult Patients With Classic Galactosemia: A Survey and Interview Study

    Dec 1, 2022, 00:00

  • PCR231 Associations of Preoperative Anxiety/Depression (EQ-5D-5L) With Pre- and Postoperative Health-Related Quality of Life for Hip and Knee Replacement

    Dec 1, 2022, 00:00

  • MSR112 Evaluating Colombia's Health Insurers Efficiency in Lung Cancer Management: A Data Envelopment Analysis

    Dec 1, 2022, 00:00

  • HTA99 NICE Evaluations of Oncology Products With EMA Conditional Marketing Authorisation

    Dec 1, 2022, 00:00

  • EE457 Forecasting Social Welfare GainsFfrom Biosimilar Entries in the Basal Insulin Market

    Dec 1, 2022, 00:00

  • HTA7 Implementation of Comprehensive Criteria for Decision Making Process of Pricing and Reimbursement in Algeria

    Dec 1, 2022, 00:00

  • MSR114 Current Scenario of ‘Scenario Analysis’ in Health Economic Modelling in Oncology: A Review of NICE Appraisals

    Dec 1, 2022, 00:00

  • P26 Disinvestment Impact, Processes, Policies and Experiences Worldwide: A Systematic Review

    Dec 1, 2022, 00:00

  • EPH29 The Cost of Managing Safety Events: Ozanimod Versus Tofacitinib – A UK Perspective

    Dec 1, 2022, 00:00

  • EE656 A Cost-Utility Analysis of Avacopan for the Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, a Rare Disease, in Spain

    Dec 1, 2022, 00:00

  • HTA90 Use of General Population Utilities in NICE Highly Specialised Technology Appraisals of Treatments With the Potential to Restore Normal Physiology

    Dec 1, 2022, 00:00

  • EE133 Budget Impact Related to Complications on Post-Bariatric Surgery Patients in Brazilian Public Healthcare System

    Dec 1, 2022, 00:00

  • HTA175 Health Technology Assessment Decisions in Sweden and Denmark: A Comparative Study in Understanding the Challenges of Approval for Single-Arm Trials

    Dec 1, 2022, 00:00

  • EE28 Cost-Effectiveness of Glucose-Lowering Therapies as Add-on to Standard Care for People With Type 2 Diabetes in Malaysia

    Dec 1, 2022, 00:00

  • EE86 Evaluation of Long- Versus Short-Term Use of Patiromer on Healthcare Resource Utilization in the Patiromer Long-Term Use Evaluation (VALUE) Study

    Dec 1, 2022, 00:00

  • HTA16 Purchasing Implantable Medical Devices in Egypt Using a Multicriteria Decision Analysis (MCDA) Tool

    Dec 1, 2022, 00:00

  • HSD68 Barriers and Facilitators of Shared Decision Making in Clinical Practi An Umbrella Review

    Dec 1, 2022, 00:00

  • MSR88 Can the Promis®-29 Profile be Used to Predict SF-36 Physical and Mental Health Summary Scores?

    Dec 1, 2022, 00:00

  • PCR269 People and Families Affected by Gsdia: An Analysis of Narrative Accounts Written by Caregivers and Individuals Living With GSDIa

    Dec 1, 2022, 00:00

  • CO4 How Can the Long-Term Benefits and Harms of Screening Be Transparently Quantified and Contrasted for Informed Decision-Making? Colorectal Cancer Screening for Persons at Familial Risk (FARKOR)

    Dec 1, 2022, 00:00

  • EE376 Cost-Effectiveness of Complete Guideline-Adherent Use of Coronary Angiography From the German Payer Perspective

    Dec 1, 2022, 00:00

  • EE448 Assessing the Cost-Effectiveness of Reducing Acute Exacerbations in Patients With COPD

    Dec 1, 2022, 00:00

  • PCR225 Quality of Life (QOL)-Related Mentions for Prevalent Diseases on Social Media Platforms in the US

    Dec 1, 2022, 00:00

  • CO30 Therapeutic Role of Melatonin in Pediatric Migraine: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • EE541 Cost-Effectiveness and Epidemiological Impact of a Novel 3-Antigen Vaccine for the Prevention of Hepatitis B in Adults in the United Kingdom

    Dec 1, 2022, 00:00

  • RWD86 Healthcare Resource Utilization (HCRU) of United States ROS1+ Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Tyrosine Kinase Inhibitors (TKIs): Analysis of Electronic Medical Transcription Records

    Dec 1, 2022, 00:00

  • EE103 Evaluating the Need for Automated Technology Solutions in Annual Therapy Cost Calculations in German Early Benefit Assessment Dossiers

    Dec 1, 2022, 00:00

  • EE630 A Cost-Effectiveness Analysis (CEA) of Adjuvant Nivolumab for Patients With Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in France

    Dec 1, 2022, 00:00

  • HTA218 Best Practices for ECA Study Design to Support HTA Decision-Making in Europe

    Dec 1, 2022, 00:00

  • HPR68 Retrospective Analysis of the Negotiation in AIFA for New Therapeutic Indications

    Dec 1, 2022, 00:00

  • HTA101 Diagnostic Testing (DTx) Costs: A Hidden Barrier to Accessing Histology-Independent Technologies (HITs)

    Dec 1, 2022, 00:00

  • EE674 Economic Burden of Patients With Glioblastoma in Five Key European Countries: A Systematic Review

    Dec 1, 2022, 00:00

  • HTA100 Association of NCPE Submission Outcomes in Ireland With Added Therapeutic Value (ASMR) Rating in France

    Dec 1, 2022, 00:00

  • RWD55 Immunosuppressive (IS) Treatment Patterns Following Kidney Transplant in Fran A Real-World Retrospective Cohort Using the French National Health Data System (SNDS) Claim Databases Oister Study

    Dec 1, 2022, 00:00
  • «
  • 31
  • 32 (current)
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • »